Department of Chemical and Biological Engineering, University of Sheffield, Sheffield, UK.
School of Biosciences, University of Sheffield, Sheffield, UK.
Biotechnol J. 2024 Jun;19(6):e2400012. doi: 10.1002/biot.202400012.
All mRNA products are currently manufactured in in vitro transcription (IVT) reactions that utilize single-subunit RNA polymerase (RNAP) biocatalysts. Although it is known that discrete polymerases exhibit highly variable bioproduction phenotypes, including different relative processivity rates and impurity generation profiles, only a handful of enzymes are generally available for mRNA biosynthesis. This limited RNAP toolbox restricts strategies to design and troubleshoot new mRNA manufacturing processes, which is particularly undesirable given the continuing diversification of mRNA product lines toward larger and more complex molecules. Herein, we describe development of a high-throughput RNAP screening platform, comprising complementary in silico and in vitro testing modules, that enables functional characterization of large enzyme libraries. Utilizing this system, we identified eight novel sequence-diverse RNAPs, with associated active cognate promoters, and subsequently validated their performance as recombinant enzymes in IVT-based mRNA production processes. By increasing the number of available characterized functional RNAPs by more than 130% and providing a platform to rapidly identify further potentially useful enzymes, this work significantly expands the RNAP biocatalyst solution space for mRNA manufacture, thereby enhancing the capability for application-specific and molecule-specific optimization of both product yield and quality.
所有的 mRNA 产品目前都是在体外转录 (IVT) 反应中生产的,该反应利用了单亚基 RNA 聚合酶 (RNAP) 生物催化剂。尽管已知离散的聚合酶表现出高度可变的生物生产表型,包括不同的相对延伸率和杂质生成谱,但通常只有少数几种酶可用于 mRNA 生物合成。这种有限的 RNAP 工具包限制了设计和解决新的 mRNA 制造工艺的策略,考虑到 mRNA 产品线不断向更大、更复杂的分子多样化,这是特别不理想的。在此,我们描述了高通量 RNAP 筛选平台的开发,该平台包括互补的计算和体外测试模块,使大规模酶库的功能特征成为可能。利用该系统,我们鉴定了八个具有相关活性同源启动子的新型序列多样化 RNAP,并随后验证了它们在基于 IVT 的 mRNA 生产过程中作为重组酶的性能。通过将可用的经过功能表征的 RNAP 数量增加了 130%以上,并提供了一个快速识别更多潜在有用酶的平台,这项工作极大地扩展了 mRNA 制造用的 RNAP 生物催化剂解决方案空间,从而增强了针对特定产品和特定分子的优化产品产量和质量的能力。